Clears hurdle for patenting Biocon’s Insulin Glargine. Biocon Ltd. today announced that the U.S. Patent and Trademark Appeal Board (PTAB) ruled in favour of Mylan, Biocon’s partner in inter-partes review (IPR) proceedings, finding all challenged claims of Sanofi’s Lantus SoloSTAR device patents unpatentable. The PTAB found three claims of patent unpatentable, and two claims to … Continue reading Biocon’s partner Mylan receives favourable ruling for device in U.S.